Gaucher Disease and the Synucleinopathies by Hruska, Kathleen S. et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2006, Article ID 78549, Pages 1–6
DOI 10.1155/JBB/2006/78549
ReviewArticle
Gaucher Disease and the Synucleinopathies
Kathleen S. Hruska, Ozlem Goker-Alpan, and Ellen Sidransky
Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute,
National Institutes of Health, Bethesda, MD 20892-3708, USA
Received 12 December 2005; Revised 5 March 2006; Accepted 15 March 2006
Several recent observations suggest a connection between Gaucher disease, the inherited deﬁciency of glucocerebrosidase, and
the synucleinopathies. Rare patients have been observed who develop both Gaucher disease and parkinsonism. Autopsy studies
on these subjects reveal synuclein-positive Lewy bodies and inclusions. An increased incidence of synucleinopathies also has been
notedinrelativesofGaucherprobands.Incomplementarystudies,screeningofpatientswithparkinsonismhasidentiﬁedagreater
than expected frequency of glucocerebrosidase mutations. These glucocerebrosidase mutation carriers have a wide spectrum of
associatedparkinsonianphenotypes,rangingfromclassicL-dopa-responsiveParkinsondiseasetoaphenotypemorecharacteristic
of Lewy body dementia. Despite this association, the vast majority of Gaucher carriers and patients with Gaucher disease never
develop parkinsonism. However, mutations in this gene are likely to be a contributing risk factor in subjects otherwise prone to
developing synucleinopathies.
Copyright © 2006 Kathleen S. Hruska et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
The synucleinopathies, including Parkinson disease (PD),
diﬀuse Lewy body dementia (DLBD), Lewy body variant of
Alzheimer disease (LBVAD), and multiple system atrophy
(MSA), are devastating adult-onset neurodegenerative dis-
eases that aﬀect millions of people worldwide. New insights
into the genetics and pathophysiology of certain synucle-
inopathies have arisen from an unexpected source: a rare
Mendelian disorder. Gaucher disease (GD) (MIM 230800,
230900, and 231000), the most common of the lipidoses, is
the recessively inherited deﬁciency of the lysosomal enzyme
glucocerebrosidase (EC.3.2.1.45). Aﬀected individuals store
the lipid glucocerebroside within lysosomes of macrophages,
resulting in characteristic-appearing Gaucher cells. Asso-
ciated clinical manifestations include hepatosplenomegaly,
anemia, thrombocytopenia, easy bleeding, and bruisability,
bony involvement and, in some cases, pulmonary involve-
ment. Gaucher disease is classiﬁed into three major clinical
types depending upon the degree of nervous system involve-
ment. Patients with type 3, or chronic neuronopathic GD,
have a varying degree of systemic involvement with at least
oneneurologicalmanifestation;patientswithtype2,oracute
neuronopathic disease, have severe neurological involvement
leading to death perinatally or in the ﬁrst years of life. Type
1, the most common form, has no associated neurological
symptoms by deﬁnition. In recent years, a small subgroup of
patients has been identiﬁed that develop parkinsonian man-
ifestations in adulthood. Several diﬀerent and complimen-




The ﬁrst indications of a relationship between Gaucher dis-
ease and parkinsonism appeared in the literature as scat-
tered case reports describing patients with Gaucher disease
who developed early-onset, treatment-refractory parkinson-
ism [1–3]. Then, in 2003, a cohort of 17 such individuals was
assembled, that included Ashkenazi Jewish probands as well
aspatientswithdiverseethnicities[4].Thepatientsinthisse-
ries had relatively mild Gaucher manifestations with a mean
age at diagnosis of 35 years. In contrast, their parkinsonian
symptoms had a rather early onset, with a mean age at diag-
nosis of 48 years. These individuals exhibited classic features,
includingasymmetrictremor,rigidity,akinesiaand,attimes,
dementia. Four subjects in this series were treated with en-
zyme replacement therapy (ERT) with recombinant human
glucocerebrosidase without any improvement or slowing of
parkinsonian symptoms. It was also noted that some of these
probands had a positive family history of parkinsonism in
hetrozygous relatives.2 Journal of Biomedicine and Biotechnology
Several other papers have described Gaucher probands
with diﬀering degrees of parkinsonian manifestations [5, 6].
Theserangedfrommildlyaﬀectedsubjectsdiagnosedintheir
70’sand80’s,toearlyonsetsubjectswhodevelopeddementia
in their 40’s. The spectrum appears to include both L-dopa-
responsive and -resistant patients. Initial presentations have
included the more classic unilateral tremor and others with
progressive rigidity. The rate of progression also has been
quite variable.
PATHOLOGICAL FINDINGS
The most consistent pathology observed in the brains from
patients with neuronopathic type 2 and type 3 GD has been
the periadventitial accumulation of Gaucher cells [7]. Sig-
niﬁcant neuronal loss with atropic neurons has been de-
scribed in the basal ganglia, nuclei of the midbrain, pons
and medulla, cerebellum, dentate nucleus, and hypothala-
mus [8, 9]. A recent neuropathological survey identiﬁed
unique patterns of disease in neuronopathic patients, con-
sisting of neuronal loss and gliosis speciﬁc to the hippocam-
pal layers CA2-4 and layer 4b of the calcarine cortex [10].
Even in subjects with type 1 GD, which, by conventional def-
inition, spares the CNS, astrogliosis of CA2 was noted.
In four individuals with Gaucher disease and parkinson-
ism, Lewy bodies were observed (Figure 2), as well as the in-
volvement of hippocampal layers CA2-4 [10, 11]. Two of the
patients had numerous intraneuronal, synuclein-positive in-
clusions in CA2-4, reminiscent of the brainstem-type Lewy
bodiesseeninthesubstantianigra(SN)ofidiopathicParkin-
son disease. The other two patients lacked these hippocam-
pal inclusions, but exhibited a Lewy body distribution con-
sistent with diﬀuse Lewy body dementia. All four subjects
exhibited hippocampal CA2-4 gliosis, depletion of SN neu-
rons, SN gliosis, and brainstem-type Lewy bodies in the SN.
GLUCOCEREBROSIDASE MUTATIONS IDENTIFIED
IN SUBJECTS WITH PARKINSON DISEASE
A molecular study was initiated to screen DNA extracted
from brain tissue of individuals with pathologically con-
ﬁrmed, idiopathic Parkinson disease for alterations in the
glucocerebroside gene (GBA). Remarkably, glucocerebrosi-
d a s em u t a t i o n sw e r ed e t e c t e di ns u c hs u b j e c t sm o r eo f t e n
thanexpected,giventhecarrierfrequencyofGaucherdisease
[11]. Direct sequencing of the entire glucocerebrosidase gene
in 57 DNA samples collected from ﬁve diﬀerent American
brainbanks revealedmutantallelesin eight(14%), including
twohomozygotesandsixheterozygotes.Fiveofthesehadone
or more alleles with the common N370S mutation, which is
speciﬁcally associated with nonneuronopathic Gaucher dis-
ease. Four additional subjects carried E326K and T369M,
which are considered polymorphic alterations in GBA. Brain
samples from 44 age-matched controls without pathologi-
c a le v i d e n c eo fP Dw e r ea l s os e q u e n c e da n dt w ow e r ef o u n d
to have the E326K allele, but no mutations were identiﬁed.
In this series, the individuals with glucocerebrosidase mu-











Figure 1: Several diﬀerent strategies are employed to elucidate
the relationship between Gaucher disease and parkinsonism. From
Sidransky [38].
(a) (b)
Figure 2: Lewy bodies seen in a patient with Gaucher disease and
parkinsonism. (a) CA2 hippocampal region demonstrating pyra-
midal cell neurons with a brainstem-type Lewy body. H&E stain,
×400 magniﬁcation. (b) Synuclein-immunoreactive Lewy bodies in
hippocampal CA4 neurons, indicated by arrowheads. Synuclein an-
tibody, Ventana, ×200 magniﬁcation. From Tayebi et al [4].
and most had documented Lewy bodies. Subsequently, DNA
from26additionalbrainsamplescollectedinBritainwerese-
quenced and two (8%) carried glucocerebrosidase mutations
[12]. These ﬁndings suggested that mutations in GBA, even
inheterozygousindividuals,mightbeaninheritedriskfactor
for the development of parkinsonism.
These ﬁndings have since been substantiated by studies
in other patient populations around the world. In many of
the subsequent studies, however, the results were obtained
by screening cohorts of patients diagnosed with Parkinson
disease for one or more speciﬁc GBA mutations. Aharon-
Peretz et al [13], in a clinic-based series of 99 Ashkenazi pa-
tients from Northern Israel with classic PD, screened blood
samples for six common mutations in glucocerebrosidase.
They identiﬁed 31 patients (31.3%) carrying glucocerebrosi-
dase mutations N370S or c.84insG, including three N370S
homozygotes. This frequency was over ﬁve-fold higher than
the frequency of GBA mutations detected in their two
control groups, which were composed of 74 patients with
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Both control groups were far from ideal, as signiﬁcant clini-
cal overlap exists between subjects carrying the diagnoses of
PD and AD, and individuals included in the Ashkenazi con-
trol group were of mixed ages and had not been screened
clinically to determine their neurological status. While the
number of PD probands with glucocerebrosidase mutations
was quite remarkable, it would be premature to attempt to
estimate the relative risk of developing parkinsonism in an
Ashkenazi individual with one or two glucocerebrosidase
mutations.
A second report [14] focused on 160 Ashkenazi Jewish
probands with Parkinson disease and 92 clinically evaluated,
age-matched controls of Jewish ancestry from a New York
City clinic. Each subject was screened for the N370S muta-
tion. Seventeen probands (10.7%) with N370S were identi-
ﬁed, including two homozygotes, as compared to 4.3% of
controls, but these results did not reach statistical signiﬁ-
cance. While this study was limited, in that only one glu-
cocerebrosidase mutation was considered, the frequency of
mutations was considerably lower than that described in the
Israeli cohort. Clearly, larger-scale studies with appropriate
controls are warranted in the Ashkenazi population.
Investigators from Toronto [15] screened for seven glu-
cocerebrosidase mutations, including two very rare alleles,
among 88 unrelated Caucasian subjects of Canadian origin
with clinically diagnosed parkinsonism. This cohort was se-
lected for an early age of onset or a positive family history,
and was compared to 122 clinically screened controls. Muta-
tions were identiﬁed in 5.6% of the cohort with Parkinson’s
disease, as compared to 0.8% of the controls.
Inafourthstudyconductedinprobandswithearly-onset
Parkinson disease from Venezuela, the entire glucocerebrosi-
dase gene was sequenced in 33 subjects and in 29 screened
controls [16]. Four unrelated probands (12%) carried three
diﬀerentglucocerebrosidasemutations.Eachofthefourwere
L-dopa-responsive, and the ages at onset ranged from 29 to
47 years of age.
Thus, independent studies, despite diﬀerences in de-
sign and ascertainment, have detected mutations in gluco-
cerebrosidase in subjects with parkinsonism at a frequency
higher than expected in some populations. The approximate
carrier frequency for GBA mutations is estimated at 0.0343
in the high-risk Ashkenazi Jewish population, and at 0.006 in
the general population [7].
PHENOTYPIC FEATURES OF GAUCHER
HETEROZYGOTES WITH PARKINSONISM
The phenotypic features encountered among subjects with
parkinsonism carrying GBA mutations are quite varied. The
group from Israel [17] compared the clinical characteristics





signiﬁcantly diﬀerent in the two groups. All of the reported
subjects had a favorable response to L-dopa. These authors
also did not ﬁnd a signiﬁcant diﬀerence in age at onset, sex,
or family history of PD. In contrast, subjects with GBA mu-
tationsidentiﬁedbythebrainbankscreeningstendedtohave
an earlier age at onset [11]. The series from Venezuela iden-
tiﬁed GBA carriers with very early-onset parkinsonism [16].
Moreover, recent analyses have suggested a high incidence of
GBA mutations in subjects who died with the diagnosis of
diﬀuse Lewy body dementia [18]. Thus, at present, the phe-
notype appears to include a wide spectrum of parkinsonian
features ranging from classic L-dopa-responsive PD to those
with early-onset symptoms or prominent dementia.
PARKINSONIAN MANIFESTATIONS AMONG RELATIVES
OF PATIENTS WITH GAUCHER DISEASE
Another indication that heterozygotes for Gaucher muta-
tions may be at risk for the development of parkinsonism
has arisen from family studies. In a small pilot project, all pa-
tients with Gaucher disease seen in the Gaucher clinics at the
National Institutes of Health over an 18-month period were
questioned speciﬁcally regarding a possible family history of
Parkinson disease or dementia. These interviews resulted in
the identiﬁcation of ten families in which obligate or con-
ﬁrmed carriers of GBA mutations developed parkinsonian
manifestations [19]. Often, these individuals were the parent
or the grandparent of the Gaucher proband.
One illustrative example was the extended family of a 7-
year-old proband with type 3 Gaucher disease, where, in the
paternal lineage, multiple family members spanning several
generations developed parkinsonism. Both aﬀected and un-
aﬀected relatives were examined and DNA samples were col-
lected.Itwasfoundthatinthisfamily,heterozygosityformu-
tation L444P correlated with Parkinson disease. In the nine
other smaller pedigrees, an obligate or conﬁrmed carrier was
shown to have parkinsonism. This study, therefore, lends ad-
ditional support to the conclusion that mutations in the glu-
cocerebrosidase gene, even in carriers, may contribute to the
development of parkinsonism.
POSSIBLE MECHANISMS FOR THE ASSOCIATION OF
GAUCHER DISEASE AND THE SYNUCLEINOPATHIES
Alpha-synuclein pathology in the brain is a feature of several
prevalent neurodegenerative disorders, including Parkinson
disease, dementia with Lewy bodies, the Lewy body vari-
ant of Alzheimer disease, and rare conditions such as mul-
tiple system atrophy and neurodegeneration with brain iron
accumulation (NBAI-1) [20]. These disorders all demon-
strate abnormal ﬁbrillization and accumulation of proteina-
ceous, insoluble alpha-synuclein inclusions in neurons and
glia, indicating a shared cellular pathology in the handling
and clearance of alpha-synuclein. Alpha-synuclein is one of
several proteins with a high propensity to aggregate. While
this protein has little or no detectable secondary structure
in solution and is considered to be natively unfolded, bind-
ing of alpha-synuclein to a number of ligands and proteins
alters this native state and leads to partially folded conforma-
tions [21]. The end products of alpha-synuclein aggregation4 Journal of Biomedicine and Biotechnology
are insoluble polymers or ﬁbrils, considered necessary for
the formation of Lewy bodies. Lewy bodies, however, con-
tain other proteins, including cytoskeletal-associated pro-
teins such as tau. A common pathological ﬁnding in the
synucleinopathies is abnormal accumulation of hyperphos-
phorylated alpha-synuclein, either with or without tau [22],
suggesting that tau may contribute to the aggregation pro-
cess. One hypothesis is that mutated glucocerebrosidase also
couldcontributetoaberrantﬁbrillizationofproteinsrespon-
sible for neurodegeneration.
It has been demonstrated that mutations in alpha-synuc-
lein result in aberrant aggregation [23]. In addition, increa-
sed expression of wild-type alpha-synuclein through gene
triplication can cause rare genetic forms of parkinsonism
throughatoxicgain-of-functionthatleadstoneuronaldeath
[24]. The pathology associated with synuclein mutations
is much more widespread and may resemble DLBD. Sim-
ilarly, the pathology observed in both Gaucher homozy-
gotes and heterozygotes encompasses the spectrum of synu-
cleinopathies, including DLBD, which might provide fur-
ther support for the hypothesis that glucocerebrosidase con-
tributes to aggregation of alpha-synuclein through a gain-of-
function mechanism.
All synuclein mutations promote formation of oligom-
ers, referred to as protoﬁbrils. Protoﬁbrils are still solu-
ble, but can form annular structures which are toxic and
might cause membrane damage [25, 26]. Soluble forms of
alpha-synuclein, such as the native wild-type form and, pos-
sibly, protoﬁbrils, are degraded via a lysosomal degrada-
tion pathway, called chaperone-mediated autophagy (CMA)
[27]. Cuervo and colleagues noted that wild-type alpha-
synuclein has a pentapeptide motif shared by other proteins
that use this pathway for degradation. Experiments in PC12
cells demonstrated that alpha-synuclein binds to the chap-
erone molecule hsc70 in the cytosol, and is then internal-
ized via a receptor, Lamp2a, on the lysosomal membrane.
Lysosomal inhibitors such as ammonium chloride blocked
this process. In contrast, mutant alpha-synuclein could still
form complexes with the chaperone, but failed to internal-
ize and remained bound to the receptor. This occupation
of Lamp2a subsequently could inhibit the degradation of
other CMA substrate proteins, resulting in a cellular log-
jam. Mutations in glucocerebrosidase, therefore, might cause
lysosomal dysfunction or interfere with receptor binding of
alpha-synuclein at the lysosomal membrane, resulting in cell
toxicity.
Other evidence indicates that the ubiquitin-proteasome
system (UPS) may be compromised in PD [28, 29]. The
accumulation and aggregation of potentially cytotoxic pro-
teins in Lewy bodies suggest generalized protein mishan-
dlingandsubsequentproteolyticstress.Thus,anothermech-
anistic possibility is that GBA mutations that result in mis-
folded protein might overwhelm the UPS ability to degrade
other abnormally accumulated proteins, including alpha-
synuclein.
Another proposed mechanism for the association of
GD and the synucleinopathies involves the potential role of
lipids. Alpha-synuclein adopts a helical conformation when
bound to lipid membranes, which would inhibit the conver-
sion into ﬁbrillar forms [30]. Other studies, however, indi-
catethatlipidscanalsopromotealpha-synucleinaggregation
and toxicity through formation of protoﬁbrils [31]. Alpha-
synuclein has been shown to bind brain-derived glycosphin-
golipids that contain glucocerebroside as their core structure
[32]. Therefore, potential changes in membrane lipid struc-
ture due to accumulation of the substrates glucocerebroside
and/or the more toxic glucosylsphingosine might enhance
bothaggregationandcytotoxicityofsynuclein,leadingtothe
pathology associated with glucocerebrosidase mutations. As
Gaucher carriers generally have no demonstrable lipid accu-
mulation, however, this mechanism appears to be less likely.
THERAPIES
At present, available treatment options for the synucle-
inopathies provide no more than a temporary slowing of
neurodegeneration and the concurrent functional deﬁcits.
The ability to prevent or delay onset is the best medical strat-
egy,butprogressintheearlydiagnosisandtreatmentofthese
disorders has been limited by an incomplete understanding
of etiology and pathogenesis.
While enzyme replacement therapy is available for pa-
tients with Gaucher disease, there is no evidence that this
treatmenthasanybeneﬁtforsubjectswithparkinsonismcar-
rying GBA mutations. First, the recombinant enzyme does
not cross the blood-brain barrier and has limited utility in
the treatment of the neurological symptoms encountered in
type 2 and 3 patients. Furthermore, several subjects with
Gaucher and parkinsonism have received ERT with no im-
provement or slowing of their neurological manifestations
[4,5].Asheterozygoteshavesuﬃcientglucocerebrosidaseac-
tivity to prevent glucocerebroside storage, additional enzyme
would not be expected to have signiﬁcant impact. Likewise,
therapies designed to reduce substrate accumulation are not
likely to be of beneﬁt. If misfolding or impaired traﬃcking of
mutant glucocerebrosidase, however, contributes to the pro-
tein aggregation encountered in the synucleinopathies, it is
possible that speciﬁc chemical chaperone therapy could be
of use in these patients.
IMPLICATIONS FOR GENETIC COUNSELING
The broader implications of these preliminary ﬁndings have
the potential to generate considerable alarm. Clearly, cau-
tion is recommended in translating these ﬁndings to the
patient community. From the general experience of treat-
ing thousands of patients with Gaucher disease, it is evi-
dent that the vast majority never develop Parkinson disease
[33]. Furthermore, it is evident that the majority of Gaucher
carriers do not have parkinsonism. Even in families where
Gaucher disease and parkinsonism is found, not all carriers
develop a neurodegenerative disorder [19]. Currently, espe-
cially in light of the diﬀerent frequencies reported in these
studies, [11, 13–16]i tw o u l db ep r u d e n tt oc o u n s e lf a m i -
lies that mutations in this gene are just one of a multitude
of potential risk factors that contribute to the developmentKathleen S. Hruska et al 5
of parkinsonism. There also are no current therapies for
Gaucher disease that would likely to be of beneﬁt to at-risk
individuals.
Forclinicians,however,awarenessofthisassociationmay
enable a better ascertainment of its frequency. Questions re-
garding a family history of tremor or dementia should be in-
cluded in the evaluation of all patients with Gaucher disease.
In addition, patients evaluated in Parkinson disease clinics
should be asked whether any relatives have Gaucher disease.
The concept of heterozygous individuals being at risk for
other disorders is not unique to Gaucher disease. There is
growing evidence that heterozygosity for a Mendelian disor-
der may be a risk factor for the development of other com-
mon complex diseases [34–37]. These preliminary data sug-
gests that heterozygosity for Gaucher mutations could be an
additional inherited risk factor in an individual otherwise
prone to parkinsonism. Explorations into the molecular and
pathophysiological mechanisms underlying this association
are being pursued aggressively, and will lead to a better un-
derstanding of both disorders.
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